Articles |
the Lipid Metabolism Laboratory (S.L.-F., E.J.S.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, and the Framingham Study (P.W.F.W.), Epidemiology Biometry Program, Framingham, Mass.
Correspondence to Stefania Lamon-Fava, MD, PhD, Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111. E-mail Fava LI@HNRC.Tufts.edu.
| Abstract |
|---|
|
|
|---|
25.00, the cutoff point for the definition of overweight. In age-adjusted analyses, BMI was significantly and linearly associated with systolic blood pressure, fasting glucose levels, plasma total cholesterol, VLDL cholesterol, and LDL cholesterol levels and was inversely and linearly associated with HDL cholesterol levels (P<.001) in nonsmoking men and women. The association between BMI and apolipoprotein B and A-I was similar to that of LDL and HDL cholesterol, respectively. LDL size was also linearly associated with BMI: subjects with higher BMI had smaller LDL particles. Lipoprotein(a) levels were not associated with BMI in this population. Of all these risk factors for CHD, reduced HDL cholesterol levels and hypertension were those more strongly associated with higher BMI in both men and women. Elevated triglyceride levels and small LDL particles, and diabetes in women, were also strongly associated with higher BMI values in this population. Our results indicate that a high prevalence of adult Americans are overweight and support the concept that increased BMI is associated with an adverse effect on all major CHD risk factors. These results emphasize the importance of excess body fat as a public health issue.
Key Words: body mass index coronary heart disease lipoproteins cholesterol blood pressure diabetes mellitus
| Introduction |
|---|
|
|
|---|
4.14 mmol/L, and HDL cholesterol levels <0.91 mmol/L as major independent risk factors for CHD.1 Some of these factors, such as age and family history of premature CHD, are nonmodifiable. However, the other risk factors can be modified through changes in lifestyle and/or drug treatment. Several epidemiological studies have demonstrated that individuals with body weight above their ideal body weight, defined by standard tables of desirable body weight such as those provided by the Metropolitan Life Insurance Company,2 3 are at increased risk of mortality from CHD.4 5 6 7 8 9 While these studies have clearly shown the positive association between increased body weight and risk of CHD, most of them did not provide clear evidence of the contribution of increased body weight to each of the major risk factors for CHD. It is thought that at least part of the increased risk of CHD conferred by an increased body weight is explained by the effects of body weight on blood pressure, glucose tolerance, and plasma lipid metabolism.10
BMI, expressed as body weight in kilograms divided by height in square meters (kg/m2), is highly correlated with body weight and poorly correlated with height11 and is frequently used as a measure of body fatness in large epidemiological studies.
In the literature, the definition of overweight and obesity, on the basis of BMI values, is somewhat confusing because different studies have used different criteria for it. For example, a body weight
20% above the ideal body weight, defined as the midpoint of the desirable weight range at a specified height, usually has been considered overweight: this corresponds to a BMI of 26.40 in men and 25.80 in women when using the 1959 Metropolitan Life Insurance tables and a BMI of 27.20 in men and 26.90 in women when using the 1983 tables.12 On the other hand, the National Health and Nutrition Examination Surveys (NHANES) studies define as overweight men with a BMI
27.80 and women with BMI
27.30 or more, corresponding to the 85th percentile in the 20- to 29-year-old subjects in that population.13 14 According to the World Health Organization, subjects with BMI between 25.00 and 30.00 are overweight, and subjects with BMI
30.00 are obese.15 Recently, the Dietary Guidelines for Americans released in 1995 define BMI >25.00 as moderate overweight and BMI >29.00 as severe overweight.16
The purpose of this study was to evaluate the distribution of BMI in a large population of white men and women and relate BMI to the prevalence of the major risk factors for CHD in this population.
| Methods |
|---|
|
|
|---|
Body weight was measured to the nearest 0.25 lb with the use of a standing beam balance and with subjects wearing only examination robes. This measurement was then converted to kilograms. Height was measured with the use of a stadiometer (to the nearest 0.25 in, and then converted to meters). BMI was calculated as the weight in kilograms divided by the square of the height in meters (kg/m2).
Hypertension was defined as the presence of a systolic blood pressure >140 mm Hg or a diastolic blood pressure >95 mm Hg or use of antihypertensive medications. Diabetes mellitus was defined as the presence of fasting serum glucose levels
7.77 mmol/L or the use of insulin or hypoglycemic medications.
Laboratory Measurements
Blood was drawn from each subject, after a 12- to 14-hour fast, in 0.1% EDTA tubes. Plasma was separated by centrifugation at 2500 rpm for 30 minutes at 4°C. Plasma was then subjected to ultracentrifugation in a Beckman 50 Ti rotor at 39 000 rpm for 18 hours at 4°C, at a density (d) of 1.006 g/mL, to separate VLDL, according to the Lipid Research Clinics methodology.18 Plasma HDL cholesterol levels were measured after the precipitation of apolipoprotein Bcontaining lipoproteins by the dextran sulfateMgCl2 method, as previously described.19 Triglyceride levels in total plasma and cholesterol levels in total plasma, the HDL supernatant, and the d 1.006 g/mL infranatant were measured by automated enzymatic techniques.20 VLDL cholesterol and LDL cholesterol levels were calculated as
![]() | (E1) |
![]() |
Plasma aliquots for the measurement of apo A-I and apo B and lipoprotein(a) levels were stored at -70°C. Apo A-I and B levels were measured by noncompetitive enzyme-linked immunosorbent assays with the use of specific affinity-purified polyclonal antiapo A-I and antiapo B antibodies, respectively.21 22
Lp(a) levels in plasma were measured with the use of a commercially available immunoassay [Macra Lp(a), Strategic Diagnostics], which uses a capturing monoclonal antiapo(a) antibody and a detecting polyclonal antibody, as previously described.23 Lp(a) was measured only in, and analyses shown for, 1228 men and 1250 women.
LDL particle size was determined (in 1433 men and 1484 women) by gradient gel electrophoresis as previously described24 and then expressed as LDL particle score, taking into account the relative areas under the peak of the major and of all minor LDL bands present in each individual.25 LDL particles were also expressed as pattern A (LDL particle score <3.5) and pattern B (LDL particle score
3.5).
The CHD risk score was calculated in each nonsmoking subject on the basis of the coronary heart disease risk factor prediction chart developed from the Framingham Heart Study26 and included individual scoring for age, total cholesterol levels, HDL cholesterol levels, systolic blood pressure, and diabetes. Scoring from left ventricular hypertrophy was not included in the final calculations. The 10-year risk of CHD in men and women was derived from the CHD risk score, as indicated in the CHD risk prediction chart.26
Statistical Analyses
Statistical analyses were performed with the SAS statistical program (SAS Institute Inc, Cary, NC). Means were calculated for all parameters in both men and women and in different age groups. The age group categories were: <30 years, 30 to 39 years, 40 to 49 years, 50 to 59 years, and
60 years. The majority of the individuals in the <30 years category were between 20 and 29 years of age, and the majority of the individuals in the
60 years category were between 60 and 69 years of age in both men and women. Subjects were also divided into 6 groups according to their BMI: <21.00, 21.00 to 22.99, 23.00 to 24.99, 25.00 to 27.49, 27.50 to 29.99, and
30.00 kg/m2. These ranges were selected because they are similar to those selected in other large epidemiological studies of men and women.5 9 27 To achieve normal distribution, a logarithmic transformation was applied to BMI, triglyceride, total cholesterol, VLDL cholesterol, HDL cholesterol, apo A-I, apo B, and Lp(a) levels in men and women and to LDL cholesterol levels in women. The PROC REG procedure was used to test the association of BMI (as a continuous variable) with blood pressure, glucose, and plasma lipid levels after adjustment for age effects and exclusion of smokers. The odds ratios for each unit of BMI increase were determined using PROC LOGIST, after the exclusion of smokers from the analysis to avoid residual effects of smoking.
| Results |
|---|
|
|
|---|
|
|
The age-related pattern of increase in BMI in men and women is also evident in Table 2
. With the use of a BMI of 25.00 as a cutoff point, there was a progressive increase in the number of overweight men and women with age. In addition, the percentage of subjects with BMI
30.00 was twofold in men and threefold in women in the 50- to 59-year age range compared with that of subjects younger than 30 years of age. The relation of BMI with age was also observed after subjects were separated by smoking habits (Fig 2
). In both smokers and nonsmokers, there was an increase of BMI with age. With the exception of the group of women <30 years of age, mean BMI was always lower in smokers than in nonsmokers in both sexes and in each age category.
|
|
When subjects were divided into six categories according to their BMI, there was a trend toward a decreased prevalence of smokers from the group with BMI <21.00 to that with BMI
30.00 (men, 50% to 24%; women, 38% to 23%).
Table 3
shows characteristics and plasma lipid levels in nonsmoking men and women according to levels of BMI. After adjustment for age effects and use of BMI as a continuous variable, there was a significant and positive linear association between BMI and blood pressure, glucose levels, and plasma triglyceride, total cholesterol, VLDL cholesterol, and LDL cholesterol levels in both men and women (Table 3
). Plasma HDL cholesterol levels significantly decreased (P<.0001) by increasing BMI, also in a linear fashion (Table 3
). Plasma apo B and apo A-I levels followed the same trend observed for LDL cholesterol and HDL cholesterol levels, respectively. Lp(a) levels were not related to BMI in this population. This was also true after Lp(a) levels were controlled for triglyceride levels (data not shown). In both men and women, the LDL size, expressed as LDL type score, decreased significantly and linearly by increasing BMI (a higher LDL score represents a smaller LDL size) (Table 3
).
|
According to their mean CHD risk score calculated from the CHD risk factor prediction chart, men and women in the group with the highest BMI were predicted to have approximately threefold the likelihood to develop CHD within 10 years than men and women in the lowest BMI group, respectively (Table 3
). After adjustment for age effects, subjects in the highest BMI group were still twofold more likely to develop CHD than subjects in the lowest BMI group (data not shown).
We determined in men and women by logistic analysis the likelihood of presenting with a CHD risk factor by increasing BMI. Smokers were excluded from the analysis to eliminate residual effects of smoking after adjustment. Table 4
shows that the prevalence of most CHD risk factors increased significantly by an increase in each one unit of BMI. The effect of BMI on high-risk total cholesterol and LDL cholesterol levels was not as strong as that on hypertension, diabetes, elevated triglycerides, and low HDL cholesterol levels. Lp(a) levels in the CHD risk range (
0.30 g/L) were not related to BMI. The likelihood of an LDL score >3.5 (or LDL type "pattern B") was strongly and significantly related to an increase in BMI. This was true also after adjustment for triglyceride levels.
|
| Discussion |
|---|
|
|
|---|
|
It is now clear that both genetic and environmental factors play an important role in the development and maintenance of obesity. The genetic component of obesity has become apparent from studies comparing monozygotic and dizygotic twins,31 and studies of monozygotic twins reared apart.32 However, genetic factors play a role in obesity within the context of energy imbalance. Energy imbalance may be caused by an increase in energy intake, a decrease in energy expenditure, or both. It is important to point out that the increase in body weight in white Americans over the past decades very likely may be caused by energy imbalance and not by genetic selection. Studies of Japanese men in Japan, Hawaii, and California have indicated that a change in diet composition toward an increase in both total fat and saturated fatty acids correlates with an increase in body weight and an increase in mortality from CHD.33 An increase in energy intake within the context of an increase in dietary fat and the same level of physical activity resulted in a significant increase in body weight over a 4- to 5-week period in Tarahumara Indians.34 Similarly, in a recent study in 27 subjects, consumption of a low fat diet (15% total fat, 5% saturated fat, 17 mg/1000 kJ cholesterol) first under isocaloric conditions for 4 to 5 weeks and then under ad libitum conditions for 10 to 12 weeks resulted in an average weight loss of 3.6 kg during the ad libitum phase.35 Weight loss in these subjects was accompanied by a significant decrease in triglyceride and LDL cholesterol levels compared with the levels during the isocaloric phase of the study.35 Therefore, diet composition may affect caloric intake and energy balance. However, it should be noted that despite a decrease in the dietary fat intake over the last decades,36 the average body weight in the US population has been increasing steadily. This probably is explained by a higher proportion of older subjects in the population, a more sedentary lifestyle, and the fact that dietary fat has been increasingly replaced by high-carbohydrate, high-energy foods, mostly provided by the food industry and not by natural foods such as fruits, vegetables, and grains.
In our population, BMI was strongly related to age, and in men the increase in BMI with age reached a plateau at age 50 years, but in women there was a constant increase of BMI with age through all age groups. Similar sex-related trends have been observed in other studies.14 Smoking is known to be a strong determinant of BMI but did not affect the association between age and BMI, in both men and women.
With the exception of Lp(a), an increase in BMI values was associated with a significant increase in the prevalence of all CHD risk factors. A positive association of body weight with blood pressure, glucose levels, and cholesterol levels has been described in previous studies.12 37 38 The lack of association between Lp(a) and BMI is not surprising, since Lp(a) levels are poorly controlled by environmental factors and are mostly genetically determined.39 We observed an association between BMI and LDL particle size. Our results indicate that LDL particle size was smaller in subjects with higher BMI both in men and women. This association was independent of triglyceride levels, which have been shown to be one of the strongest determinants of LDL size in this population.24 25 After controlling for age and smoking effects, our analysis showed that the relationship between all lipoprotein parameters and BMI is linear, indicating that the "optimal" levels of BMI are toward lower values. With the use of the CHD risk prediction chart, there was approximately a twofold age-adjusted increase in the 10-year risk of CHD in subjects in the group with BMI
30.00 kg/m2 than in those with BMI <21.00 kg/m2. This is consistent with the observed increased risk of CHD by BMI reported in other studies.5 6 10 40 41
Our results clearly indicate that the effects of increasing BMI on total cholesterol and LDL cholesterol levels, though significant, are relatively modest in both men and women. Of all known risk factors for CHD, reduced HDL cholesterol levels, and hypertension were those more strongly associated with higher BMI in both men and women. In addition, diabetes in women and elevated triglyceride levels and small LDL particles were also strongly associated with higher BMI values in this population.
BMI is widely used as a measure of fatness in epidemiological studies because it has been shown that this index is highly correlated with body fat and is nearly independent of height.11 Densitometry is currently considered the gold standard in the measurement of body fatness, and correlations of BMI and densitometry approximate 0.6.11 Body composition in some of the participants in the Framingham Offspring Study also has been measured by bioelectric impedance, a more precise method of estimating body fat, and BMI, though correlated with the bioelectric impedance measurement, did not explain all variability in fatness in this population.42 This indicates that BMI may not reliably represent body fat in individuals. This is particularly true in men and is due to the fact that BMI is mostly a measure of weight and therefore does not discriminate between body fat and lean mass. Taking this into account, it is likely that the contribution of body fatness to cardiovascular risk factors in the Framingham Offspring population is even greater than that derived by our analyses.
Our data indicate that BMI is highly correlated with most risk factors for CHD and that prevention of overweight is an important public heath issue. Treatment of excess body weight through lifestyle changes, such as an increase in physical exercise and a decrease in energy intake and fat intake, is advisable for the general population. In addition, addressing the trend toward an increase in body weight observed in several affluent societies through early education during childhood may be the most important step in the prevention of future CHD.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received January 17, 1996;
revision received May 7, 1996;
| References |
|---|
|
|
|---|
2. Metropolitan Life Insurance Company. New weight standards for men and women. Stat Bull Metrop Life Insur Co. 1959;40:1-4.
3. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Insur Co. 1983;64:2-9.
4.
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
5. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and coronary heart disease in women. N Engl J Med. 1990;322:882-889.[Abstract]
6.
Curb JD, Marcus EB. Body fat, coronary heart disease, and stroke in Japanese men. Am J Clin Nutr. 1991;53:1612S-1615S.
7. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992;327:1350-1355.[Abstract]
8.
Lee I-M, Manson JE, Hennekens CH, Paffenbarger RS. Body weight and mortality: a 27-year follow-up of middle-aged men. JAMA. 1993;270:2823-2828.
9.
Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333:677-685.
10.
Van Itallie TB. Obesity: adverse effects on health and longevity. Am J Clin Nutr. 1979;32:2723-2733.
11. Willett W. Nutritional Epidemiology. New York, NY: Oxford University Press; 1990:217-244.
12. National Institutes of Health Consensus Development Panel on the Health Implications of Obesity. Health implications of obesity: National Institutes of Health consensus development conference statement. Ann Intern Med. 1985;103:1073-1077.
13. Najjar MF, Rowland M. Anthropometric Reference Data and Prevalence of Overweight, United States, 1976-1980. Washington, DC: Vital Health Statistics II; Dept of Health and Human Services publication No. (PH5) 87-1688.
14. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272;205-211.
15. World Health Organization. Measuring Obesity. Classification and Description of Anthropometric Data. Copenhagen, Denmark: WHO; 1989.
16. Dietary Guidelines Advisory Committee. Nutrition and Your Health: Dietary Guidelines for Americans, 1995. US Dept of Agriculture and US Dept of Health and Human Services. 4th ed. Washington, DC: US Government Printing Office. 1995.
17.
Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
18. Manual of Laboratory Operations, Lipid Research Clinics Program. Lipid and Lipoprotein Analysis. Vol 1. Bethesda, Md: National Heart, Lung, and Blood Institute; DHEW Publication No. (NIH) 75-628. 1974.
19.
Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
20. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.[Medline] [Order article via Infotrieve]
21. Ordovas JM, Peterson JP, Santaniello P, Cohn JS, Wilson PWF, Schaefer EJ. Enzyme-linked immunosorbent assay for human plasma apolipoprotein B. J Lipid Res. 1987;28:1216-1224.[Abstract]
22. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871-882.[Abstract]
23.
Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87:1135-1141.
24.
McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 1987;7:483-490.
25.
Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BP, Wilson PWF, Castelli WP, Schaefer EJ. LDL particle size distribution: results from the Framingham Offspring Study. Arterioscler Thromb. 1992;12:1410-1419.
26.
Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
27.
Denke MA, Sempos CT, Grundy SM. Excess body weight: an underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med. 1993;153:1093-1103.
28. Shah M, Hannan PJ, Jeffery RW. Secular trends in body mass index in the adult population of three communities from the upper midwestern part of the USA: the Minnesota Heart Health Program. Int J Obes. 1991;15:499-503.[Medline] [Order article via Infotrieve]
29. James WPT. Epidemiology of obesity. Int J Obes. 1992;16:S23-S26.
30. WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. World Health Stat Q. 1988;41:115-140.[Medline] [Order article via Infotrieve]
31.
Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA. 1986;256:51-54.
32. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. N Engl J Med. 1990;322:1483-1487.[Abstract]
33. Robertson TL, Kato H, Rhoads GG, Kagan A, Marmot M, Syme SL, Gordon T, Worth RM, Belsky JL, Dock DS, Miyanishi M, Kawamoto S. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol. 1977;39:239-243.[Medline] [Order article via Infotrieve]
34. McMurry MP, Cerqueira MT, Connor SL, Connor WE. Changes in lipid and lipoprotein levels and body weight in Tarahumara Indians after consumption of an affluent diet. N Engl J Med. 1991;325:1704-1708.[Abstract]
35.
Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Schaefer MM, Rasmussen H, Ordovas JM. Body weight and low density lipoprotein cholesterol changes after consumption of an ad libitum low fat diet. JAMA. 1995;274:1450-1455.
36. National Center for Health Statistics, McDowell MA, Briefel RR, et al. Energy and Macronutrient Intakes of Persons Ages 2 Months and Over in the United States: Third National Health and Nutrition Examination Survey, Phase I, 1988-1991. Advance Data From Vital and Health Statistics. No. 255. Washington, DC: Public Health Service; DHHS Publication No. (PHS) 95-1250. 1995.
37.
Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension: a review. Circulation. 1969;39:403-412.
38.
Kannel WB, Gordon T, Castelli WP. Obesity, lipids, and glucose intolerance: the Framingham Study. Am J Clin Nutr. 1979;32:1238-1245.
39. Boerwinkle E, Leffert CC, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
40.
Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity: a reassessment. JAMA. 1987;257:353-358.
41. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. JAMA. 1995;273;461-465.
42.
Roubenoff R, Dallal GE, Wilson PWF. Predicting body fatness: the body mass index vs estimation by bioelectrical impedance. Am J Public Health. 1995;85:726-728.
This article has been cited by other articles:
![]() |
N. C. Cavarocchi Invited commentary. Ann. Thorac. Surg., February 1, 2009; 87(2): 546 - 547. [Full Text] [PDF] |
||||
![]() |
S. E. Chiuve, M. L. McCullough, F. M. Sacks, and E. B. Rimm Healthy Lifestyle Factors in the Primary Prevention of Coronary Heart Disease Among Men: Benefits Among Users and Nonusers of Lipid-Lowering and Antihypertensive Medications Circulation, July 11, 2006; 114(2): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Shaw, C. N. Bairey Merz, C. J. Pepine, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, S. Mankad, B. L. Sharaf, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S4 - S20. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wilsgaard, B. K. Jacobsen, and E. Arnesen Determining Lifestyle Correlates of Body Mass Index using Multilevel Analyses: The Tromso Study, 1979-2001 Am. J. Epidemiol., December 15, 2005; 162(12): 1179 - 1188. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Yalcin, E. M. Sahin, and E. Yalcin Which anthropometric measurements is most closely related to elevated blood pressure? Fam. Pract., October 1, 2005; 22(5): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lamon-Fava, J. B. Barnett, M. N. Woods, C. McCormack, J. R. McNamara, E. J. Schaefer, C. Longcope, B. Rosner, and S. L. Gorbach Differences in Serum Sex Hormone and Plasma Lipid Levels in Caucasian and African-American Premenopausal Women J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4516 - 4520. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. St-Pierre, B. Cantin, P. Mauriege, J. Bergeron, G. R. Dagenais, J.-P. Despres, and B. Lamarche Insulin resistance syndrome, body mass index and the risk of ischemic heart disease Can. Med. Assoc. J., May 10, 2005; 172(10): 1301 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mora, L. R. Yanek, T. F. Moy, M. D. Fallin, L. C. Becker, and D. M. Becker Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families Circulation, April 19, 2005; 111(15): 1871 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oh, F. B. Hu, J. E. Manson, M. J. Stampfer, and W. C. Willett Dietary Fat Intake and Risk of Coronary Heart Disease in Women: 20 Years of Follow-up of the Nurses' Health Study Am. J. Epidemiol., April 1, 2005; 161(7): 672 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L Pelkman, V. K Fishell, D. H Maddox, T. A Pearson, D. T Mauger, and P. M Kris-Etherton Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women Am. J. Clinical Nutrition, February 1, 2004; 79(2): 204 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, and V. K. Somers Body Mass Index: A Risk Factor for Unstable Angina and Myocardial Infarction in Patients With Angiographically Confirmed Coronary Artery Disease Circulation, November 4, 2003; 108(18): 2206 - 2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Shapo, J Pomerleau, and M McKee Epidemiology of hypertension and associated cardiovascular risk factors in a country in transition: a population based survey in Tirana City, Albania J Epidemiol Community Health, September 1, 2003; 57(9): 734 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, K. E. Yarasheski, and S. Klein Alterations in lipid kinetics in men with HIV-dyslipidemia Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E490 - E497. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhu, Z. Wang, W. Shen, S. B Heymsfield, and S. Heshka Percentage body fat ranges associated with metabolic syndrome risk: results based on the third National Health and Nutrition Examination Survey (1988-1994) Am. J. Clinical Nutrition, August 1, 2003; 78(2): 228 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mittendorfer, B. W. Patterson, S. Klein, and L. S. Sidossis VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E708 - E715. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mittendorfer, B. W Patterson, and S. Klein Effect of sex and obesity on basal VLDL-triacylglycerol kinetics Am. J. Clinical Nutrition, March 1, 2003; 77(3): 573 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mittendorfer, B. W. Patterson, and S. Klein Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E549 - E556. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. F. Wilson, R. B. D'Agostino, L. Sullivan, H. Parise, and W. B. Kannel Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience Arch Intern Med, September 9, 2002; 162(16): 1867 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.F. Ebenbichler, M. Laimer, S. Kaser, A. Ritsch, A. Sandhofer, H. Weiss, F. Aigner, and J.R. Patsch Relationship Between Cholesteryl Ester Transfer Protein and Atherogenic Lipoprotein Profile in Morbidly Obese Women Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1465 - 1469. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J Schaefer Lipoproteins, nutrition, and heart disease Am. J. Clinical Nutrition, February 1, 2002; 75(2): 191 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Gaunt, J. A. Cooper, G. J. Miller, I. N.M. Day, and S. D. O'Dell Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males Hum. Mol. Genet., July 1, 2001; 10(14): 1491 - 1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Holvoet, A. Mertens, P. Verhamme, K. Bogaerts, G. Beyens, R. Verhaeghe, D. Collen, E. Muls, and F. Van de Werf Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 844 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Rainwater, B. D. Mitchell, A. G. Comuzzie, J. L. VandeBerg, M. P. Stern, and J. W. MacCluer Associations among 5-Year Changes in Weight, Physical Activity, and Cardiovascular Disease Risk Factors in Mexican Americans Am. J. Epidemiol., November 15, 2000; 152(10): 974 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Olson, S. F. Kelsey, V. Bittner, S. E. Reis, N. Reichek, E. M. Handberg, C. N. Bairey Merz, and for the Women's Ischemia Syndrome Evaluation (WISE Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: A report from the NHLBI-sponsored WISE study J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1565 - 1571. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.S. Kilpatrick, B.G. Keevil, C. Jagger, R.J. Spooner, and M. Small Determinants of raised C-reactive protein concentration in type 1 diabetes QJM, April 1, 2000; 93(4): 231 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Bairey Merz, S. F. Kelsey, C. J. Pepine, N. Reichek, S. E. Reis, W. J. Rogers, B. L. Sharaf, G. Sopko, and for the WISE Study Group The Women's Ischemia Syndrome Evaluation (WISE) Study: protocol design, methodology and feasibility report J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1453 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pietrobelli, R. C Lee, E. Capristo, R. J Deckelbaum, and S. B Heymsfield An independent, inverse association of high-density-lipoprotein-cholesterol concentration with nonadipose body mass Am. J. Clinical Nutrition, April 1, 1999; 69(4): 614 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Borson-Chazot, C. Harthe, F. Teboul, F. Labrousse, C. Gaume, L. Guadagnino, B. Claustrat, F. Berthezene, and P. Moulin Occurrence of Hyperhomocysteinemia 1 Year after Gastroplasty for Severe Obesity J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 541 - 545. [Abstract] [Full Text] |
||||
![]() |
T. Rönnemaa, J. Marniemi, M. J. Savolainen, Y. A. Kesäniemi, C. Ehnholm, C. Bouchard, and M. Koskenvuo Serum Lipids, Lipoproteins, and Lipid Metabolizing Enzymes in Identical Twins Discordant for Obesity J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2792 - 2799. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |